Last chance! 50% off unlimited learning
Sale ends in
The function Single.Trial.RE.AA
conducts a surrogacy analysis based on the single-trial meta-analytic framework of Buyse & Molenberghs (1998). See Details below.
Single.Trial.RE.AA(Dataset, Surr, True, Treat, Pat.ID, Alpha=.05,
Number.Bootstraps=500, Seed=sample(1:1000, size=1))
A data.frame
that should consist of one line per patient. Each line contains (at least) a surrogate value, a true endpoint value, a treatment indicator, and a patient ID.
The name of the variable in Dataset
that contains the surrogate values.
The name of the variable in Dataset
that contains the true endpoint values.
The name of the variable in Dataset
that contains the treatment indicators. The treatment indicator should either be coded as
The name of the variable in Dataset
that contains the patient's ID.
The
The number of bootstrap samples that are used to obtain the bootstrapp-based confidence intervals for RE and the adjusted association (
The seed that is used to generate the bootstrap samples. Default sample(x=1:1000, size=1)
, i.e., a random number between 1 and 1000.
An object of class Single.Trial.RE.AA
with components,
Prior to conducting the surrogacy analysis, data of patients who have a missing value for the surrogate and/or the true endpoint are excluded. Data.Analyze
is the dataset on which the surrogacy analysis was conducted.
An object of class data.frame
that contains the parameter estimate for Alpha
is not to be confused with the Alpha
argument in the function call, which specifies the
An object of class data.frame
that contains the parameter estimate for
An object of class data.frame
that contains the estimated RE, its standard error, and its confidence interval (based on the Delta method).
An object of class data.frame
that contains the estimated RE, its standard error, and its confidence interval (based on Fieller's theorem).
An object of class data.frame
that contains the estimated RE, its standard error, and its confidence interval (based on bootstrapping). Note that the occurence of outliers in the sample of bootstrapped RE values may lead to standard errors and/or confidence intervals that are not trustworthy. Such problems mainly occur when the parameter estimate for RE.Boot.Samples
below) is recommended in this situation, and/or the use of the confidence intervals that are based on the Delta method or Fieller's theorem (rather than the bootstrap-based confidence interval).
An object of class data.frame
that contains the adjusted association (i.e.,
An object of class data.frame
that contains the adjusted association (i.e.,
A vector that contains the RE values that were generated during the bootstrap procedure.
A vector that contains the adjusted association (i.e.,
A data.frame
that contains the correlations between the surrogate and the true endpoint in the control treatment group (i.e.,
A data.frame
that contains the residuals for the surrogate and true endpoints that are obtained when the surrogate and the true endpoint are regressed on the treatment indicator.
The Relative Effect (RE) and the adjusted association (
where the error terms have a joint zero-mean normal distribution with variance-covariance matrix:
and where
The parameter estimates of the fitted regression model and the variance-covariance matrix of the residuals are used to compute RE and the adjusted association (
Note
The single-trial meta-analytic framework is hampered by a number of issues (Burzykowski et al., 2005). For example, a key motivation to validate a surrogate endpoint is to be able to predict the effect of Z on T as based on the effect of Z on S in a new clinical trial where T is not (yet) observed. The RE allows for such a prediction, but this requires the assumption that the relation between UnifixedContCont
, BifixedContCont
, UnimixedContCont
, and BimixedContCont
).
Burzykowski, T., Molenberghs, G., & Buyse, M. (2005). The evaluation of surrogate endpoints. New York: Springer-Verlag.
Buyse, M., & Molenberghs, G. (1998). The validation of surrogate endpoints in randomized experiments. Biometrics, 54, 1014-1029.
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000). The validation of surrogate endpoints in meta-analysis of randomized experiments. Biostatistics, 1, 49-67.
Kutner, M. H., Nachtsheim, C. J., Neter, J., & Li, W. (2005). Applied linear statistical models (5th ed.). New York: McGraw Hill.
UnifixedContCont
, BifixedContCont
, UnimixedContCont
, BimixedContCont
, ICA.ContCont
# NOT RUN {
# time consuming code part
# Example 1, based on the ARMD data:
data(ARMD)
# Assess surrogacy based on the single-trial meta-analytic approach:
Sur <- Single.Trial.RE.AA(Dataset=ARMD, Surr=Diff24, True=Diff52, Treat=Treat, Pat.ID=Id)
# Obtain a summary and plot of the results
summary(Sur)
plot(Sur)
# Example 2
# Conduct an analysis based on a simulated dataset with 2000 patients
# and Rindiv=.8
# Simulate the data:
Sim.Data.STS(N.Total=2000, R.Indiv.Target=.8, Seed=123)
# Assess surrogacy:
Sur2 <- Single.Trial.RE.AA(Dataset=Data.Observed.STS, Surr=Surr, True=True, Treat=Treat,
Pat.ID=Pat.ID)
# Show a summary and plots of results
summary(Sur2)
plot(Sur2)
# }
Run the code above in your browser using DataLab